ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 82 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2020. The put-call ratio across all filers is 1.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,777,119 | -11.7% | 1,368,039 | +0.1% | 0.00% | -33.3% |
| Q2 2023 | $3,144,190 | -24.6% | 1,367,039 | -0.7% | 0.01% | -25.0% |
| Q1 2023 | $4,170,865 | +30.1% | 1,376,523 | 0.0% | 0.01% | +33.3% |
| Q4 2022 | $3,207,000 | +23.1% | 1,376,523 | +0.9% | 0.01% | 0.0% |
| Q3 2022 | $2,606,000 | -29.5% | 1,364,523 | 0.0% | 0.01% | -25.0% |
| Q2 2022 | $3,698,000 | -9.1% | 1,364,523 | -0.0% | 0.01% | 0.0% |
| Q1 2022 | $4,066,000 | -23.4% | 1,364,524 | -0.0% | 0.01% | -20.0% |
| Q4 2021 | $5,309,000 | -9.3% | 1,364,894 | +0.0% | 0.01% | -16.7% |
| Q3 2021 | $5,854,000 | +41.1% | 1,364,564 | -0.4% | 0.01% | +33.3% |
| Q2 2021 | $4,150,000 | -9.0% | 1,369,689 | -0.0% | 0.01% | -18.2% |
| Q1 2021 | $4,562,000 | -6.3% | 1,370,089 | -0.1% | 0.01% | -15.4% |
| Q4 2020 | $4,868,000 | +14.3% | 1,371,089 | +0.8% | 0.01% | 0.0% |
| Q3 2020 | $4,258,000 | +31.8% | 1,360,289 | -23.4% | 0.01% | +18.2% |
| Q2 2020 | $3,230,000 | +80.1% | 1,774,935 | +0.0% | 0.01% | +57.1% |
| Q1 2020 | $1,793,000 | – | 1,774,915 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 340,000 | $1,459,000 | 0.53% |
| RTW INVESTMENTS, LP | 4,733,323 | $20,306,000 | 0.31% |
| APIS CAPITAL ADVISORS, LLC | 70,000 | $300,000 | 0.29% |
| Hudson Bay Capital Management LP | 1,800,000 | $7,722,000 | 0.10% |
| COWEN AND COMPANY, LLC | 249,215 | $1,069,000 | 0.05% |
| Kerrisdale Advisers, LLC | 100,000 | $429,000 | 0.05% |
| Woodline Partners LP | 496,172 | $2,129,000 | 0.04% |
| Shay Capital LLC | 60,000 | $257,000 | 0.03% |
| Walleye Capital LLC | 231,037 | $991,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 212,700 | $912,000 | 0.02% |